American Society of Hirudotherapy

Unusual, Uncommon, Intriguing, and Significant Causes of Kounis Syndrome: Important Medications and Chemicals Used to Treat Kounis Syndrome and Myocardial Infarction Can Cause Kounis Syndrome

Kounis NG, de Gregorio C, Hung MY, Giamouzis G, Michalaki MA, Özkan U, Ceasovschih A, Mplani V, Dousdampanis P, Kouni SN, Stefanidis A, Nastouli KM, Bozika M, Patsouras N, Koniari I (2025) · Journal of Cardiovascular Development and Disease

Expert opinion / guidance: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Type
narrative review of mast-cell-mediated Kounis (allergic) coronary syndrome with explicit discussion of hirudotherapy as a recognized trigger of mast cell degranulation and acute coronary ischemia (multicenter international authorship: Greece, Italy, Taiwan, Turkey, Romania, UK)
Scope
Narrative synthesis of case literature implicating hirudotherapy (whole-leech application) and several anti-thrombotic / anti-ischemic medications (heparin, protamine, adrenaline, aspirin, clopidogrel, corticosteroids) as Kounis syndrome triggers

Key Findings

  • Hirudotherapy explicitly identified as a recognized trigger of Type I (allergic vasospasm) and Type II (allergic plaque rupture) Kounis syndrome
  • Mast-cell mediators (histamine, tryptase, chymase, arachidonic acid derivatives) drive the cascade — consistent with biology of leech-bite hypersensitivity
  • Clinical conundrum noted: multiple drugs used to TREAT Kounis (epinephrine, heparin, aspirin, corticosteroids) can also trigger it — relevant when managing leech-bite reactions
  • Authors recommend physician awareness when patients with allergic history receive hirudotherapy
  • Adds to the growing safety-context literature alongside Tas 2025 (leech-bite Kounis case) and Wanandy 2024 (Tasmania anaphylaxis)

Limitations

  • Narrative review — does not provide incidence estimates for hirudotherapy-related Kounis syndrome
  • Case literature on leech-bite Kounis remains small (single-digit case reports)
  • Mechanistic discussion based on extrapolation from other mast-cell-mediated triggers
  • No prospective screening data for at-risk leech-therapy patients
  • Review covers a heterogeneous mix of triggers — leech therapy is one of many

Clinical Implications

Kounis 2025 adds an important cardiology-allergy safety signal to ASH's leech-therapy literature. For US clinicians administering hirudotherapy under the K040187 device indication, the review reinforces that patients with known mast-cell disorders, hymenoptera allergy, or prior leech hypersensitivity should be screened pre-procedure and treated only in monitored settings with rapid access to epinephrine. The review complements existing case-report literature (Tas 2025, Wanandy 2024) and supports current ASH practice of informed-consent disclosure of rare anaphylactic risk.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.